Reading all about those problems (delays, protocol, FDA incompetence, ...) why is Cytodyn insisting to do the mCRC trial in the USA? Why not check if some other goverment body around the world is more open for discussions?
Why should we do and finance a trial with a suboptimal design, which delays us and does not put the patients first? Are we wasting another 2-3 years?